Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1970 3
1971 2
1972 2
1973 4
1974 7
1975 13
1976 22
1977 16
1978 14
1979 19
1980 14
1981 31
1982 51
1983 44
1984 46
1985 24
1986 30
1987 11
1988 19
1989 19
1990 14
1991 16
1992 14
1993 20
1994 10
1995 11
1996 15
1997 11
1998 13
1999 24
2000 15
2001 11
2002 5
2003 17
2004 9
2005 8
2006 15
2007 15
2008 7
2009 8
2010 18
2011 25
2012 18
2013 17
2014 14
2015 17
2016 20
2017 33
2018 14
2019 15
2020 12
2021 22
2022 18
2023 14
2024 15
2025 12
2026 5

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

892 results

Results by year

Filters applied: . Clear all
Page 1
Loxapine for schizophrenia.
Fenton M, Murphy B, Wood J, Bagnall A, Chue P, Leitner M. Fenton M, et al. Cochrane Database Syst Rev. 2000;(2):CD001943. doi: 10.1002/14651858.CD001943. Cochrane Database Syst Rev. 2000. Update in: Cochrane Database Syst Rev. 2007 Oct 17;(4):CD001943. doi: 10.1002/14651858.CD001943.pub2. PMID: 10796455 Updated.
BACKGROUND: Loxapine is a drug with D2/D3 receptor antagonist activity and a higher affinity for D3 than D2. ...Very limited heterogeneous data suggest that, given intramuscularly (IM), loxapine may be at least as sedating as IM haloperidol and thiothixene. REVIEWER …
BACKGROUND: Loxapine is a drug with D2/D3 receptor antagonist activity and a higher affinity for D3 than D2. ...Very limited heteroge …
Loxapine for schizophrenia.
Chakrabarti A, Bagnall A, Chue P, Fenton M, Palaniswamy V, Wong W, Xia J. Chakrabarti A, et al. Cochrane Database Syst Rev. 2007 Oct 17;2007(4):CD001943. doi: 10.1002/14651858.CD001943.pub2. Cochrane Database Syst Rev. 2007. PMID: 17943763 Free PMC article.
OBJECTIVES: To determine the effects of loxapine compared with placebo, typical and other atypical antipsychotic drugs for schizophrenia and related psychoses. ...Very limited heterogeneous data suggest that, given intramuscularly (IM), loxapine may be at least as s …
OBJECTIVES: To determine the effects of loxapine compared with placebo, typical and other atypical antipsychotic drugs for schizophre …
Second-generation antidepressants.
Rudorfer MV, Golden RN, Potter WZ. Rudorfer MV, et al. Psychiatr Clin North Am. 1984 Sep;7(3):519-34. Psychiatr Clin North Am. 1984. PMID: 6237317 Review.
Tardive myoclonus.
Little JT, Jankovic J. Little JT, et al. Mov Disord. 1987;2(4):307-11. doi: 10.1002/mds.870020408. Mov Disord. 1987. PMID: 3504556
Evaluation of amoxapine.
Kinney JL, Evans RL Jr. Kinney JL, et al. Clin Pharm. 1982 Sep-Oct;1(5):417-24. Clin Pharm. 1982. PMID: 6764165 Review.
Amoxapine is a tricyclic dibenzoxazepine antidepressant that is chemically similar to the antipsychotic agent loxapine. In animal tests, amoxapine and its metabolites block reuptake of the neurotransmitter norepinephrine, with little effect on serotonin. ...
Amoxapine is a tricyclic dibenzoxazepine antidepressant that is chemically similar to the antipsychotic agent loxapine. In animal tes …
The new antidepressants.
Golden RN, Brown TM, Miller H, Evans DL. Golden RN, et al. N C Med J. 1988 Oct;49(10):549-54. N C Med J. 1988. PMID: 3054572 Review. No abstract available.
Loxapine abuse.
Sperry L, Hudson B, Chan CH. Sperry L, et al. N Engl J Med. 1984 Mar 1;310(9):598. doi: 10.1056/nejm198403013100920. N Engl J Med. 1984. PMID: 6694719 No abstract available.
[Progress through formulation].
Oberpichler-Schwenk H. Oberpichler-Schwenk H. Med Monatsschr Pharm. 2013 Jul;36(7):243. Med Monatsschr Pharm. 2013. PMID: 23898601 German. No abstract available.
892 results